Park Ha Biological Technology C (BYAH): Financials
Fiscal year ended October 31, 2025
Income statement, cash flow and balance sheet figures for Park Ha Biological Technology C (BYAH), read directly from the XBRL data the company files with the SEC. Over the most recent fiscal year the company reported $2.5M of revenue, up 6.0% year over year. Net loss was $24.4M, or $-41.38 per diluted share. Free cash flow was -$3.0K. Gross margin stood at 94.4%.
Against the current share price, BYAH trades at 0.7 times trailing revenue.
4 fiscal years of history are available, back to 2022.
Frequently asked questions
How much revenue does BYAH make?
Park Ha Biological Technology C reported $2.5M of revenue over the most recent fiscal year, for the period ended October 31, 2025. That is up 6.0% from the same period a year earlier.
Is BYAH profitable?
Park Ha Biological Technology C was unprofitable over the most recent fiscal year, with a net loss of $24.4M.
Where does this financial data come from?
Every figure on this page is read from the company's own SEC 10-Q and 10-K filings. Nothing is estimated by a third party. Quarterly figures a company does not file separately (most commonly the fourth quarter) are derived by subtracting the reported year-to-date quarters from the full fiscal year, and are labelled as derived.
What is the difference between quarterly, annual and TTM?
Quarterly shows each three-month fiscal period on its own. Annual shows the full fiscal year as filed in the 10-K. TTM (trailing twelve months) sums the last four reported quarters, which is the most current annualised view between 10-K filings.